Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

NCT00659399 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Low accrual

Conditions

Ovarian Carcinoma

Interventions

DRUG: Fondaparinux

Sponsor

NYU Langone Health

Collaborators

[object Object]